Leading the Way in Life Science Technologies

GEN Exclusives

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

June 15, 2007 (Vol. 27, No. 12)

Opening the Gates on Ion Channel Drugs

Conditions Targeted Include Diabetes, Cystic Fibrosis, Hypertension, Pain and Cancer

  • Ion channels continue to generate tremendous excitement as therapeutic targets. Blockbusters such as Norvasc (hypertension), Ambien (insomnia), and Xanax (anxiety) exemplify how ion channel therapeutics generate more than $12 billion in revenues annually. Serving as gatekeepers that modulate ions such as potassium, sodium, and calcium, these membrane proteins ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.